For example, SST0001, a modified heparin, significantly reduces in vivo heparanase activity and controls levels of growth factors including HGF and VEGF, thereby preventing angiogenesis in human pediatric sarcoma models (Cassinelli et al., 2013). This evidence concerns the gene VEGFA and sarcoma.